U.S. markets closed
  • S&P Futures

    4,167.50
    -8.75 (-0.21%)
     
  • Dow Futures

    33,995.00
    -86.00 (-0.25%)
     
  • Nasdaq Futures

    14,015.50
    -14.00 (-0.10%)
     
  • Russell 2000 Futures

    2,250.60
    -8.40 (-0.37%)
     
  • Crude Oil

    62.87
    -0.26 (-0.41%)
     
  • Gold

    1,776.60
    -3.60 (-0.20%)
     
  • Silver

    25.88
    -0.23 (-0.88%)
     
  • EUR/USD

    1.1947
    -0.0033 (-0.27%)
     
  • 10-Yr Bond

    1.5730
    +0.0430 (+2.81%)
     
  • Vix

    16.25
    -0.32 (-1.93%)
     
  • GBP/USD

    1.3817
    -0.0023 (-0.17%)
     
  • USD/JPY

    108.6430
    -0.1400 (-0.13%)
     
  • BTC-USD

    56,881.61
    -3,504.90 (-5.80%)
     
  • CMC Crypto 200

    1,288.47
    -103.24 (-7.42%)
     
  • FTSE 100

    7,019.53
    +36.03 (+0.52%)
     
  • Nikkei 225

    29,647.94
    -35.43 (-0.12%)
     

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of QS, TCDA and HSACW

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / March 1, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

QuantumScape Corporation f/k/a Kensington Capital Acquisition Corp. (NYSE:QS)
Class Period: November 27, 2020 - December 31, 2020
Lead Plaintiff Deadline: March 8, 2021

The QS lawsuit alleges that throughout the class period, QuantumScape Corporation f/k/a Kensington Capital Acquisition Corp. made materially false and/or misleading statements and/or failed to disclose that: (1) that the Company's purported success related to its solid-state battery power, battery life, and energy density were significantly overstated; (2) that the Company is unlikely to be able to scale its technology to the multi-layer cell necessary to power electric vehicles; and (3) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in QS: http://www.kleinstocklaw.com/pslra-1/quantumscape-corporation-f-k-a-kensington-capital-acquisition-corp-loss-submission-form?id=13191&from=1

Tricida, Inc. (NASDAQ:TCDA)
Class Period: September 4, 2019 - October 28, 2020
Lead Plaintiff Deadline: March 8, 2021

The complaint alleges that during the class period Tricida, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Tricida's NDA for veverimer was materially deficient; (ii) accordingly, it was foreseeably likely that the FDA would not accept the NDA for veverimer; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in TCDA: http://www.kleinstocklaw.com/pslra-1/tricida-inc-loss-submission-form?id=13191&from=1

Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation (NASDAQ:HSACW)
Class Period: October 2, 2019 - February 1, 2021
Lead Plaintiff Deadline: April 20, 2021

According to the complaint, Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) HSAC had performed inadequate due diligence into Legacy Immunovant prior to the Merger, and/or ignored or failed to disclose safety issues associated with IMVT-1401; (ii) IMVT-1401 was less safe than the Company had led investors to believe, particularly with respect to treating TED and WAIHA; (iii) the foregoing foreseeably diminished IMVT-1401's prospects for regulatory approval, commercial viability, and profitability; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in HSACW: http://www.kleinstocklaw.com/pslra-1/immunovant-inc-f-k-a-health-sciences-acquisitions-corporation-loss-submission-form?id=13191&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm



View source version on accesswire.com:
https://www.accesswire.com/632726/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-QS-TCDA-and-HSACW